Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT01281943

Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer

Phase II Study of Pegylated Liposomal Doxorubicin (Doxil®) and Temsirolimus (Torisel®) in Patients With Advanced Hepatocellular Cancer

Status
Withdrawn
Phase
Phase 2
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Washington University School of Medicine · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This Phase II study will use the MTD from a previous Phase I study at the recommended dose for the combination regimen from the Phase I trial, Doxil 25mg/m2 IV Q 4 weeks and temsirolimus 25mg IV Q week.

Detailed description

This proposal aims to capitalize on the consensus recommendations of the NCI panel, the known antitumor activity of doxorubicin in HCC, and the as yet unpublished results of a recently completed Phase I clinical trial (WU HRPO# 07-0447, NCT00703170) combining pegylated liposomal doxorubicin (Doxil®) and temsirolimus (Torisel®) in patients with advanced solid tumors. In this Phase I study, twenty-two patients were enrolled and treated. The MTD and recommended Phase II dose for the combination regimen from this trial is is Doxil 25mg/m2 IV Q 4 weeks and temsirolimus 25mg IV Q week. During the conduct of this study two patients experienced confirmed partial responses (PR). One patient had heavily pretreated metastatic breast cancer and remained on the study for 6 months. The second patient with a PR had HCC that was previously treated with sorafenib. She remained on the study regimen for 14 months and tolerated this treatment well. Based on the tolerability of the drug combination and the observed anti-tumor activity in HCC, the current Phase II study in HCC is proposed.

Conditions

Interventions

TypeNameDescription
DRUGTemsirolimus 25mg and Pegylated liposomal doxorubicin 25mg/m2Temsirolimus 25mg IV on days 1, 8, 15 and 22 of each 28 day cycle Pegylated liposomal doxorubicin 25mg/m2 IV on day 1 of each 28 day cycle

Timeline

Start date
2011-06-01
Primary completion
2012-07-01
Completion
2014-05-01
First posted
2011-01-24
Last updated
2013-07-04

Source: ClinicalTrials.gov record NCT01281943. Inclusion in this directory is not an endorsement.